OCT 03, 2018 10:30 AM PDT

Integrating Novel Advances in Gene Delivery and Genome Engineering for Therapeutic Application

Presented at: CRISPR 2018
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor of Chemical and Biomolecular Engineering, Department of Bioengineering, Director of the Berkeley Stem Cell Center, University of California at Berkeley
    Biography
      David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at the University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He received a B.S. in Chemical Engineering from Stanford University in 1993 and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology in 1998. He then conducted a postdoctoral fellowship at the Salk Institute for Biological Studies before becoming a faculty member at the University of California, Berkeley in 1999. At Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions. Dr. Schaffer has received an NSF CAREER Award, Office of Naval Research Young Investigator Award, Whitaker Foundation Young Investigator Award, and was named a Technology Review Top 100 Innovator. He was also awarded the American Chemical Society Marvin Johnson Award in 2016, the American Chemical Society BIOT Division Young Investigator Award in 2006, the Biomedical Engineering Society Rita Shaffer Young Investigator Award in 2000, and was inducted into the College of Fellows of the American Institute of Medical and Biological Engineering in 2010.

    Abstract

    There have been an increasing number of successful human gene therapy clinical trials, and in particular gene delivery vehicles or vectors based on the adeno-associated virus (AAV) have enabled success in trials for hemophilia B, spinal muscular atrophy, X-linked myotubular myopathy, and Leber’s congenital amaurosis type 2 (LCA2). The LCA2 trials led to the first FDA approval of a gene therapy for rare disease in the US in December, 2017.  That said, vectors based on natural versions of AAV face a number of delivery challenges that limit their efficacy and will thus preclude the extension of these successes to the majority of human diseases.  These delivery limitations arise since the parent viruses upon which these vectors are based were not evolved by nature for our convenience to use as human therapeutics.  We have been developing and implementing a high throughput approach termed directed evolution – involving the iterative genetic diversification of a viral genome and functional selection for desired properties – to engineer highly optimized variants of AAV for a broad range of cell and tissue targets.

    In parallel, the advent of genome editing technologies such as the CRISPR/Cas9 system raise the possibility of using gene delivery not only for gene replacement but for repair or knockout of endogenous genes.  We have thus been combining engineered AAVs with CRISPR/Cas9 for a range of applications.  For example, delivery of a Cas9 targeting mutant superoxide dismutase (SOD1) in a murine model of amyotrophic lateral sclerosis delayed the onset of disease symptoms and significantly extended animal lifespan.  In addition, we engineered an AAV for enhanced transport along neuronal axons, and delivery of Cas9 enabled the knockout of specific genes in vivo within projection neurons from a distance, work with both basic and translational applications.  Finally, we have combined AAV delivery of donor constructs with Cas9 ribonucleoproteins to effect efficient homologous recombination within in genomic target loci.  The integration of these new technologies – Cas9 cargo with AAV delivery – can thus enable a broad range of basic and therapeutic applications.

    Learning Objectives: 

    1. Adeno-associated viral vectors have the capacity to mediate efficient delivery of CRISPR/Cas9, leading to effective genome editing in vivo.
    2. As a result, CRISPR/Cas9 is an effective tool to knock out autosomal dominant alleles that underlie human disease.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources
    Attendees
    • See more